BASEL, Switzerland I 11, 2025 I Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, ...

Company plans to initiate a Phase 1/b trial in relapsed/refractory, locally advanced/metastatic bladder cancer by year-end ...

INGELHEIM, Germany I 10, 2025 I Boehringer Ingelheim announced today that the FIBRONEER™-ILD trial met its primary endpoint, which was the ...

RALEIGH, NC, USA I 10, 2025 I Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ("Intas ...

BRISBANE, Australia & INDIANAPOLIS, IN, USA I 10, 2025 I AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha ...

PASADENA, CA, USA I 10 2025 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement ...

Orca Bio to present efficacy and safety data with Orca-T compared to conventional allogeneic hematopoietic stem cell transplant (alloHSCT) at the 51st Annual ...

NEW TAIPEI CITY, Taiwan I February 9, 2025 I Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), ...

OLX75016: A GWAS-derived therapeutic targeting MASH, liver fibrosis, and other cardiometabolic indications SEONGNAM, South Korea I 10, 2025 I OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading ...

SHANGHAI, China I 10, 2025 I On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products ...

Bayer submitted an application to the European Medicines Agency (EMA) to expand treatment intervals of up to 6 months with Eylea™ 8 mg (aflibercept 8 mg, ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...